Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 1-2, 2009, Pages 33-38

  Kosacka, Monika ^a   Jankowska, Renata ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

CYFRA 21 1; Cytokeratin 19; Non small cell lung cancer

Indexed keywords

CYTOKERATIN 19; CYTOKERATIN 19 FRAGMENT;

ADULT; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; PROTEIN EXPRESSION;

EID: 61349152260     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.598     Document Type: Article

References (33)

1. Ktyszejko-Stefaniak L. [Keratin filaments). In: Kłyszejko- Stefaniak L: [Cy-tobiochemistry - biochemistry of some cell structures]. PWN, Warszawa 2002:141-146. Polish.
2. Fuchs E. Keratins as biochemical markers of epithelial differentiation. Trends Genet. 1988; 4: 277-281.
3. Moll R. Cytokeratins as markers of differentiation. Expression profiles in epithelia and epithelial tumors. Veroff Pathol. 1993; 142: 1 -197.
4. Fei W, Nishioka M, Fujita J, et al. Expression of cytokeratin 19 in human hepatocellular carcinoma cell lines. Int J Oncol. 2002; 20: 31 -37.
5. Bader BL, Jahn L, Franke WW. Low level expression of cytokeratin 8,18 and 19 in vascular smooth muscle cells of human umbilical cord and in cultured cell derived there from, with an analysis of the chromosomal locus containing the cytokeratin 19 gene. J Cell Biol. 1988; 47: 300-319.
6. Fradette J, Germain L, Seshaiah P, et al. The type I keratin 19 possesses distinct and context dependent assembly properties. J Biol Chem. 1998; 272:176-184.
7. Stasiak PC, Purkis PE, Leigh IM, et al. Keratin 19 predicted amino acid sequence and broad tissue distribution suggest it evolved from keratino-cyte keratins. J Invest Dermatol. 1989; 92: 707-716.
8. Lindberg K, Rheinwald JG. Suprabasal 40 kd keratin (K19) expression as an immunohistologic marker of premalignancy in oral epithelium. Amer J Pathol. 1989; 134: 89-98.
9. Dobashi N, Fujita J, Murota M, et al. Binding of recombinant human cytokeratin 19 to laminin:a possible role in interaction between intermediate filament derived from epithelial cells and extracellular matrixes. Cell Struct Funct. 2000; 25:171-175.
10. Takei Y, Minato K, Tsuchiya S, et al. CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer. Oncol. 1997; 54: 43-47.
11. Pujol JL, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small cell lung cancer: results of meta-analysis in 2063 patients. Br J Cancer. 2004; 90: 2097-2105.
12. Sánchez-Carbayo M, Espasa A, Chinchilla V, et al. New electrochemi-luminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem. 1999; 45:1944-1953.
13. Nikliński J, Burzykowski T, Niklińska W, et al. Preoperative CYFRA 21-1 level as prognostic indicator in resected non small cell lung cancer. Eur Respir J. 1998; 12:1424-1428.
14. Skuladottir H, Olsen JH. Epidemiology of lung cancer. In: Spiro SG, ed. Lung cancer, Volume 6, Monograph. ERS Journals Ltd, Sheffield 2001:1-12.
15. Lienert T, Serke M, Loddenkemper R. Lung cancer in young females. Eur Respir J. 2000; 16: 986-990.
16. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995; 75:191-202.
17. Survival of Cancer Patients in Europe: the Eurocare-3 study. Ann Oncol. 2003; vol. 14, supplement, http://eurocare.i1/18. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA. 2000; 283: 2975-2978.
18. Alberts WM. Updated ACCP guidelines for the diagnosis and management of lung cancer - what are the important changes in recommendations? Pol Arch Med Wewn. 2008; 118:4-5.
19. Chyczewski L, Niklinski J, Chyczewska E, et al. Immunohistochemical analysis of tissue localization of cytokeratin 19 in lung cancer. Rocz Akad Med Bialymst. 1997; 42:162-172.
20. Dohmoto K, Hojo S, Fujita J, et al. Mechanisms of the release of CYFRA 21-1 in human lung cancer. Lung Cancer. 2000; 30: 55-63.
21. Ueda Y, Fujita J, Bandoh S, et al. Expression of cytokeratin 19 mRNA in human lung cancer cell lines. Int J Cancer. 1999; 81:939-943.
22. Dohmoto K, Hojo S, Fujita J, et al. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA 21-1) in human lung cancer cell lines. Int J Cancer. 2001; 91:468-473.
23. Wu F, Fujita J, Murota M, et al. CYFRA 21-1 is released in TNF-al-pha-induced apoptosis in the hepatocellular carcinoma cell line HuH-7. Int J Oncol. 2002;21:441-445.
24. Sheard MA, Vojtesek B, Simickova M, et al. Release of cytokeratin 18 and 19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem. 2002; 85:670-677.
25. Nakamura H, Abe S, Shibata Y, et al. Elevated levels of cytokeratin 19 in the bronchoalveolar lavage fluid of patients with chronic airway inflammatory diseases: a specific marker for bronchial epithelial injury. Am J Respir Crit Care Med. 1997; 155:1217-1221.
26. Nakayama M, Satoh H, Ishikawa H, et al. Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases. Chest. 2003; 123: 2001-2006.
27. Dobashi N, Fujita J, Ohtsuki Y, et al. Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneumonia. Eur Respir J. 1994; 14: 574-578.
28. Ge MJ, Shi D, Wu QC, et al. Observation of circulating tumour in patients with non -small cell lung cancer by real-time fluorescent quantitative reverse transcriptase-polymerase chain reaction in perioperative period. J Cancer Res Clin Oncol. 2006; 132: 248-256.
29. Fujita J, Kawakami K, Matsuhashi Y, et al. The pitfall in evaluating several serological markers of Pneumocystis carinii pneumonia in a neutropenic patient. Intern Med. 2000; 39: 659-662.
30. Lai RS, Hsu HK, Lu JY, et al. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Chest. 1996; 109: 995-1000.
31. Huang MS, Jong SB, Lin MS, et al. Cytokeratin fragment 19(CYFRA 21-1) as a tumor marker in non-small cell lung cancer. Kaohisiung J Med Sci. 1996; 12: 62-68.
32. Sugama Y, Kitamura S, Kawai T, et al. The clinical usfulness of CYFRA 21-1 assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res. 1994; 85:1178-1184.
33. Tournoy KG, van Meerbeeck JR New American College of Chest Physicians guidelines on mediastinal staging and management of stage IIIA-N2 non-small cell lung cancer: a European perspective. Pol Arch Med Wewn. 2008; 118: 175-178.